Last week, Gilead’s remdesivir received its first positive scientific opinion from the Medicines and Healthcare products Regulatory Agency (MHRA) under the Early Access to Medicines Scheme (EAMS) for use in Covid-19 patients.
GlobalData suspects that remdesivir will target a select severity group of Covid-19 patients, with the question of how it will be best to initiate and optimise treatment of the disease with the drug. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
